No Quick-Fix Solution

New York - While the micronized formulation of Alloderm (Cymetra, LifeCell Corp.) is an appropriate substance for correcting certain facial defects, the physician who wants to use it may need to manage patient expectations, according to Anthony P. Sclafani, M.D.

Related Videos
Related Content

HS Treatment Response Rates Continue to Improve with Secukinumab at Week 52

February 3rd 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Losing a Malpractice Case May Depend on Where You Live

February 3rd 2023

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

November 4th 2021

The Role We Play in Addressing Racial Disparity in Dermatology

February 2nd 2023

The Mainstream Patient: February 2

February 2nd 2023

HS Treatment Response Rates Continue to Improve with Secukinumab at Week 52

February 3rd 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Losing a Malpractice Case May Depend on Where You Live

February 3rd 2023

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

November 4th 2021

The Role We Play in Addressing Racial Disparity in Dermatology

February 2nd 2023

The Mainstream Patient: February 2

February 2nd 2023

HS Treatment Response Rates Continue to Improve with Secukinumab at Week 52

February 3rd 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Losing a Malpractice Case May Depend on Where You Live

February 3rd 2023

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

November 4th 2021

The Role We Play in Addressing Racial Disparity in Dermatology

February 2nd 2023

The Mainstream Patient: February 2

February 2nd 2023
Advertise
Contact Us
Job Board
Do Not Sell My Information
Terms and Conditions
Privacy Policy
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.